Anti-idiotypic antibodies specific for HLA in heart and kidney allograft recipients.
Chronic rejection is the major threat to both heart and renal allograft survival. We have explored the possibility that some patients with anti-donor HLA antibodies (Ab1) develop specific anti-idiotypic antibodies (Ab2) which suppress the production of Ab1, and subsequently, the progression of chronic rejection. Analysis of Ab2 in sera obtained from Ab1 producers showed that 22% of heart and 18% of kidney recipients produced Ab2. The 4- and 5-year actuarial graft survivals in Ab2 producers were 100% and 83%, respectively, compared to 57% in patients who formed Ab1 but not Ab2 (p < 0.004). Patients carrying the DR2 alleles, DRB1*1501, *1502 or *1601 were at a lower risk of producing anti-donor HLA antibodies.
Reed
E
E
College of Physicians and Surgeons of Columbia University, Department of Pathology, New York, NY 10032.
Ho
E
E
Cohen
D J
DJ
Ramey
W
W
Marboe
C
C
D'Agati
V
V
Rose
E A
EA
Hardy
M
M
Suciu-Foca
N
N
D000483:Alleles; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D005838:Genotype; D006085:Graft Survival / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D006684:HLA-DR Antigens / Q000235:genetics / Q000276:immunology; D059811:HLA-DRB1 Chains; D016027:Heart Transplantation / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology; D006801:Humans; D007518:Isoantibodies / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D015993:Life Tables
D000888:Antibodies, Anti-Idiotypic; D006680:HLA Antigens; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D000949:Histocompatibility Antigens Class II; D007518:Isoantibodies